Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Mylan's Alphapharm victorious in Razadyne patent challenge

Mylan Inc. has announced that its subsidiary Alphapharm Pty Limited won a favorable decision in patent litigation against it and Barr Laboratories Inc. relating to Galantamine Tablets, USP, the generic version of Ortho-McNeil's Razadyne Tablets, 4 mg, 8 mg and 12 mg.

31 Aug 2008

Sex differences found in response to common antidepressant

Women with depression may be much more likely than men to get relief from a commonly used, inexpensive antidepressant drug, a new national study finds. But many members of both sexes may find that it helps ease their depression symptoms.

31 Aug 2008

Medicare overpaid for prescription drugs with new generic versions because of delay in incorporating new prices into payment calculations

Medicare overpaid for irinotecan, a cancer drug sold by Pfizer under the name Campostar, by $6.5 million in March because of a delay in updating its pricing formula, according to a report released on Tuesday by the HHS Office of Inspector General, Bloomberg/Los Angeles Times reports.

29 Aug 2008

Ortho-McNeil to appeal patent ruling on Razadyne

Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced that it will appeal yesterday's decision by the U.S. District Court of Delaware, which ruled the patent for Razadyne (galantamine hydrobromide) is invalid.

28 Aug 2008

Barr receives U.S. approval for generic Razadyne tablets

Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc., received final approval from the U.S. Food & Drug Administration (FDA) to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne (galantamine hydrobromide), 4 mg, 8 mg and 12 mg tablets. Barr intends to launch its generic Razadyne tablets product immediately.

28 Aug 2008

Meda settles U.S. Astelin patent litigation with Cobalt

Meda, through its wholly owned U.S. subsidiary, Meda Pharmaceuticals Inc., has entered into a settlement agreement with Cobalt Pharmaceuticals Inc. (hereafter Cobalt) that resolves the U.S. patent litigation between the companies regarding Cobalt's proposed generic version of Astelin.

25 Aug 2008

Intel's CTO says technology will bring man and machine much closer together by 2050

Intel Corporation's chief technology officer took a fascinating look at how technology will bring man and machine much closer together by 2050.

21 Aug 2008

eHealth closer to reality thanks to real-time relevant medical data extraction

In the framework of Holst Centre, IMEC - Europe's leading independent nanoelectronics research institute - has broadened the functionality and scope of its wireless health monitoring technology by linking it to real-time extraction of relevant medical data.

20 Aug 2008

Actavis receives approval of generic Wellbutrin in U.S.

Actavis Group today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 300mg. Distribution of the product will commence immediately.

18 Aug 2008

Watson announces ruling in Naproxen sodium patent case

Watson Pharmaceuticals, Inc. announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan, infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent").

13 Aug 2008

Barr Labs to settle Mirapex and Aggrenox patent challenges

Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.

12 Aug 2008

IMPAX sued for patent infringement on generic Ultram ER

IMPAX Laboratories, Inc. today announced Purdue Pharma Products L.P. ("Purdue"), Napp Pharmaceutical Group Ltd. ("Napp"), Biovail Laboratories International, SRL ("Biovail") and Ortho-McNeil, Inc. ("Ortho-McNeil") have filed suit for patent infringement in the United States District Court for the District of Delaware based on the Company's submission of its Abbreviated New Drug Application ("ANDA") for tramadol hydrochloride extended-release tablets (100 mg), generic of Ultram ER, to the Food and Drug Administration.

12 Aug 2008

Mexico lifts regulation requiring AIDS drug companies to have manufacturing plants in Mexico in order to sell generics

On the day of the opening ceremonies of the XVII International AIDS Conference in Mexico City, President Felipe Calderon announced his plans to lift a Mexican Ministry of Economy requirement that pharmaceutical companies operating in Mexico must have a manufacturing plant in that country in order to use or sell generic versions of their lifesaving AIDS and other drugs in Mexico.

4 Aug 2008

Barr confirms Xyzal tablet patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiaries, Barr Laboratories, Inc. and PLIVA-Hrvatska D.O.O., have initiated a challenge of the patent listed by UCB Inc. in connection with its Xyzal(R) Tablets (levocetirizine dihydrochloride), 5mg.

31 Jul 2008

A counter to counterfeit drugs

The counterfeiting of medicines has been known of since around 1990 and is a growing problem-in both developing and developed countries. Counterfeit medicines are estimated as more than 10% of the global medicines market and in some developing countries it is thought to be as high as 50%. One prediction is that global counterfeit drug sales will reach $75 billion by 2010.

30 Jul 2008

Barr confirms patent challenge of Sensipar tablets

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Amgen Inc. in connection with its Sensipar Tablets (cincalcet hydrochloride), 30mg, 60mg and 90mg.

29 Jul 2008

FDA approves first generic divalproex sodium for the treatment of seizures, bipolar disorder and migraine headaches

The U.S. Food and Drug Administration today approved the first generic versions of Depakote delayed-release tablets (divalproex sodium). Depakote is approved by the FDA for the treatment of seizures, bipolar disorder and migraine headaches.

29 Jul 2008

Barr confirms Fentora tablet patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Cephalon, Inc. in connection with its Fentora(R) Tablets (fentanyl citrate buccal tablets), equivalent to fentanyl base 100 mcg, 400 mcg, 600 mcg and 800 mcg.

24 Jul 2008

CMS proposal would limit industry practice that raises costs for some Medicare drug plan beneficiaries

A CMS proposal under consideration would limit a practice used by pharmacy benefit managers known as "lock-in pricing" that can increase costs for beneficiaries enrolled in the Medicare drug benefit and bring them into the so-called "doughnut hole" coverage gap more quickly, the Wall Street Journal reports.

23 Jul 2008

Patent for Aciphex ruled valid and enforceable

PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Federal Circuit Court of Appeals affirmed the judgments of the United States District Court for the Southern District of New York that the patent for Aciphex (rabeprazole sodium 20 mg tablets) is valid and enforceable.

21 Jul 2008